WallStreetZenWallStreetZen

NASDAQ: VCYT
Veracyte Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Veracyte earnings were $114.5M for the trailing 12 months ending Jun 30, 2026, with 311.4% growth year over year. The latest VCYT earnings report on Jun 30, 2026 announced Q2 2026 earnings of $25.5M, down 11.2% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, VCYT reported annual earnings of $66.4M, with 174.9% growth.

VCYT past earnings growth

How has VCYT's earnings growth performed historically?

Company
311.43%
Industry
15.84%
Market
90.96%
VCYT's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
VCYT's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Market Performance
VCYT's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

VCYT earnings history

Current Revenue
$561.9M
Current Earnings
$114.5M
Current Profit Margin
20.4%

VCYT Return on Equity

Current Company
8.6%
Current Industry
-13.7%
Current Market
29%
VCYT's Return on Equity (8.6%)... subscribe to Premium to read more.
High Return on Equity Performance

VCYT Return on Assets

Current Company
8%
Current Industry
-10.4%
VCYT is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when VCYT announces earnings.

VCYT Return on Capital Employed

Current Company
8.15%
Current Industry
-6.8%
VCYT has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

VCYT vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
VCYT$139.68M$114.48M+311.43%$1.44
QURE-$171.01M-$252.21MN/A-$4.01
ABCL-$167.78M-$164.66MN/A-$0.54
NAMS-$294.61M-$294.89MN/A-$2.46
GPCR-$209.62M-$214.84MN/A-$3.03
View Top Biotech Stocks

Veracyte Earnings Reports & History FAQ

What were Veracyte's earnings last quarter?

On VCYT's earnings call on Jul 30, 2026, Veracyte (NASDAQ: VCYT) reported Q2 2026 earnings per share (EPS) of $0.32, up 3,300% year over year. Total VCYT earnings for the quarter were $25.49 million. In the same quarter last year, Veracyte's earnings per share (EPS) was -$0.01.

If you're new to stock investing, here's how to buy Veracyte stock.

Is Veracyte profitable or losing money?

As of the last Veracyte earnings report, Veracyte is currently profitable. Veracyte's net profit (also called net income) for the twelve months ending Jun 30, 2026 was $114.48 million, a 334.72% increase year over year.

What was VCYT's earnings growth in the past year?

As of Veracyte's earnings date in Jul 30, 2026, Veracyte's earnings has grown 311.43% year over year. This is 295.59 percentage points higher than the US Biotechnology industry earnings growth rate of 15.84%. VCYT earnings in the past year totalled $114.48 million.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.